Zura Bio Ltd (ZURA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN USG9TY5A1012
Zura Bio Ltd financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -75.25 m USD |
| EBIT | -74.99 m USD |
| Net income | -68.65 m USD |
| Diluted EPS – continuing operations | -1.06 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Zura Bio Ltd
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
More stocks
- Moens Bank A/S (MNBA.CO)
- Gatekeeper Systems Inc (GSI.V)
- Acusensus Ltd (ACE.AX)
- Votum SA (VOT.WA)
- Everybot Inc. (270660.KQ)
- Harleysville Financial Corp (HARL)
- Dynacolor (5489.TWO)
- Eusu Holdings (000700.KS)
- FDC International Hotels Corp (2748.TW)
- Mega Uranium Ltd. (MGA.TO)
- Bogota Financial Corp. (BSBK)
- Dynagas LNG Partners LP (DLNG)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.